biostudies-literatureUnknown79(6)van der Wekken-Pas LThis case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1468-1471https://www.ebi.ac.uk/biostudies/studies/S-EPMC11650856biostudies-literatureLong-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV.PMC11650856Burger DWeiss Fvan Leeuwen Evan der Wekken-Pas LSebisch RWiese CSimon-Zuber CColbers AfalseLong-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV.This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.2024-01-01T00:00:00Z2024 Dec2025-04-04T01:09:25.758Z2025-04-04T01:09:25.758ZS-EPMC116508563870338810.1093/cid/ciae242